Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 6,498 Shares

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. This trade represents a 5.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The stock was sold at an average price of $10.53, for a total value of $113,018.49.

Bioventus Stock Down 3.6 %

Shares of BVS opened at $9.95 on Friday. The stock’s 50-day moving average price is $10.34 and its two-hundred day moving average price is $10.82. Bioventus Inc. has a 12 month low of $3.90 and a 12 month high of $14.38. The company has a market capitalization of $807.44 million, a PE ratio of -16.31 and a beta of 0.85. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Analysts Set New Price Targets

Several equities analysts recently commented on BVS shares. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group increased their price target on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC acquired a new position in Bioventus during the 3rd quarter worth approximately $89,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Bioventus in the third quarter valued at about $286,000. Olympiad Research LP bought a new position in shares of Bioventus during the third quarter valued at about $251,000. Principal Financial Group Inc. purchased a new position in Bioventus during the third quarter worth about $210,000. Finally, Covestor Ltd bought a new stake in Bioventus in the 3rd quarter worth about $69,000. 62.94% of the stock is owned by institutional investors.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.